Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arrowhead Pharmaceuticals...

    NASDAQ: ARWR · Real-Time Price · USD
    16.07
    -0.75 (-4.46%)
    At close: May 30, 2025, 3:59 PM
    16.06
    -0.06%
    After-hours: May 30, 2025, 04:58 PM EDT
    -4.46%
    Bid 15.85
    Market Cap 2.22B
    Revenue (ttm) 545.21M
    Net Income (ttm) -146.55M
    EPS (ttm) -1.24
    PE Ratio (ttm) -12.96
    Forward PE -4.96
    Analyst Buy
    Ask 16.23
    Volume 1,255,205
    Avg. Volume (20D) 1,879,304
    Open 16.78
    Previous Close 16.82
    Day's Range 15.68 - 16.78
    52-Week Range 9.57 - 30.41
    Beta 0.90

    About ARWR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ARWR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +9.38%
    Arrowhead Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription
    2 weeks ago
    +7.21%
    Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
    news image

    2 days ago · businesswire.com

    Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Glo...

    news image

    2 weeks ago · seekingalpha.com

    Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Chris...

    news image

    3 weeks ago · businesswire.com

    Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securiti...

    news image

    1 month ago · businesswire.com

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss ...

    news image

    1 month ago · businesswire.com

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will reti...

    news image

    1 month ago · businesswire.com

    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Co...

    news image

    2 months ago · seekingalpha.com

    Arrowhead Pharmaceuticals Is Finally Arriving

    Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reducti...

    news image

    2 months ago · businesswire.com

    Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investiga...

    news image

    2 months ago · businesswire.com

    Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical s...

    news image

    3 months ago · businesswire.com

    Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healt...

    Add to Watchlist